osteoporosis
Conditions
Interventions
eldecalcitol for 48 weeks
Sponsors
Shimane University Faculty of Medicine
Nakaoka clinic Tai clinic Chibune Hospital:endocrinology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Primary osteoporotic patients 2.Postmenopausal type 2 diabetes patients with more than 6.5% of HbA1c 3.Patients with informed of consent
Exclusion criteria
Exclusion criteria: 1.Patients who have taken bisphosphonate treatments 2.Patients who have taken medicine such as SERMs, glucocorticoid, vitamin K, active vitamin D, calcitonin, insulin within two months from the day of eldecalcitol dosage 3.Patients who are inappropriate for this study by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Change of lumbar spine bone mineral density 2.Change of total hip bone mineral density | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.X-ray of thoracolumbar(Number of fracture occurred) 2.Body composition 3.Blood and urinaly biochemical test(FBS, HbA1c, IRI, CRP, Cr, CK, CRP, Alb, Ca, P, T-Chol, Homocysteine, Pentosidine, Adiponectin, Sclerostin, esRAGE, DKK-1, 25(OH)D, Urinaly Ca, Urinaly Cr, Urinaly Alb, Urinaly NTX) 4.Muscular strength/Balance function test(Grasping power, Open eyes standing on one leg test) 5.Safety | — |
Countries
Japan
Contacts
Public ContactMika Yamauchi
Shimane University Faculty of Medicine Internal Medicine 1
Outcome results
None listed